Login to your account
Don’t have an account?
Create a Free Account
Homepage
Tackling antimicrobial resistance & securing sustainable access to antibiotics
-
Future health expenditures and its determinants in Latin America and the Caribbean: a multi-country projection study
Increases in health expenditures will be driven largely by economic growth and technology, while demography and epidemiology had smaller effects. The control of health expenditures and more efficient use of health resources must become a priority for the LAC region. -
Supporting self-management of low back pain with an internet intervention with and without telephone support in primary care (SupportBack 2): a randomised controlled trial of clinical and cost-effectiveness
The SupportBack internet interventions did not significantly reduce low back pain-related disability over 12 months compared with usual care. They were likely to be cost-effective and safe. Clinical effectiveness, cost-effectiveness, and safety should be considered together when determining whether to apply these interventions in clinical practice. -
Relative efficacy of masks and respirators as source control for viral aerosol shedding from people infected with SARS-CoV-2: a controlled human exhaled breath aerosol experimental study
These results suggest that N95 respirators could be the standard of care in nursing homes and healthcare settings when respiratory viral infections are prevalent in the community and healthcare-associated transmission risk is elevated. -
Inflammatory risk and cardiovascular events in patients without obstructive coronary artery disease: the ORFAN multicentre, longitudinal cohort study
The FAI Score captures inflammatory risk beyond the current clinical risk stratification and CCTA interpretation, particularly among patients without obstructive CAD. The AI-Risk integrates this information in a prognostic algorithm, which could be used as an alternative to traditional risk factor-based risk calculators.
Theranostics in Oncology
The Lancet Oncology
Published: May 28, 2024
The clinical use of diagnostic and therapeutic radiopharmaceuticals—theranostics—in oncology has expanded rapidly over the past decade with regulatory approval for therapeutic use in neuroendocrine tumours and prostate cancer. In the first paper in this four-part Series, Suzanne Lapi and colleagues summarise the current landscape of radiopharmaceutical sciences in oncology including progress in radiochemistry and the production of radionuclides, the development and use of theranostics, and the application of artificial intelligence. In the second paper, Andrew Scott and colleagues discuss the challenges of building a global workforce to achieve equitable access to theranostics. Francesco Giammarile and colleagues explore issues that affect access to, and availability of, theranostic radiopharmaceuticals in the third-part of this Series. And, in the final paper, May Abdel-Wahab and colleagues examine the current state of radiotherapy research in low-income and middle-income countries and explore ways to advance novel radiotherapy research opportunities in resource-constrained settings.
Addressing migration and health inequity in Europe
The Lancet Regional Health – Europe
Published: May 28, 2024
Strong policies to ensure the health and wellbeing of migrants—the most neglected population group in any country—are desperately lacking. Shockingly, less than half of the member states in the WHO European Region report health data for migrants, highlighting a systemic failure to prioritise their wellbeing, despite 36% of the global migrant population residing in Europe.
This Series addresses the urgent need to tackle the pressing health challenges faced by migrants in Europe. It takes a comprehensive approach, incorporating various perspectives such as social, political, economic, medical anthropological, public health, medical education, and humanitarian medicine.
The Series identifies seven key areas (corresponding to the seven papers) crucial for Europe to transition from migrant health inequity to migrant health equity, aligning with the 2030 Sustainable Development Goals agenda of leaving no one behind. Addressing these areas will help cultivate a more inclusive and equitable health-care system for migrants in Europe.
The Lancet Breast Cancer Commission
The Lancet
Published: April 15, 2024
Despite tremendous advances in breast cancer research and treatment over the past three decades—leading to a reduction in breast cancer mortality of over 40% in some high-income countries—gross inequities remain, with many groups being systematically left behind, ignored, and even forgotten. The work of the Lancet Breast Cancer Commission highlights crucial groups, such as those living with metastatic breast cancer, and identifies how the hidden costs of breast cancer and associated suffering are considerable, varied, and have far-reaching effects. The Commission offers a forward-looking and optimistic road map for how the health community can course correct to address these urgent challenges in breast cancer.
The Lancet Commission on prostate cancer: planning for the surge in cases
The Lancet
Published: April 4, 2024
Prostate cancer is already a major cause of morbidity and mortality worldwide and the prostate cancer commission projects that the number of new cases will double between 2020-2040. The commission analysis both immediate and long-term interventions to mitigate the current and projected future global impact of prostate cancer. The burden of disease globally is already substantial but there areas of cancer care highlighted by the commission, where technology, patient empowerment and simple practice change innovations can advance cancer control. Opportunities are available from the diagnostic pathway to the management of advanced disease and need to be urgently implemented to better prepare patients and healthcare providers, to respond to the current and future burden of prostate cancer. The Lancet Commission on prostate cancer provides an agenda for a realistic programme of changes, which, if implemented, will improve the health of men globally both now and in future.
- The Lancet
- The Lancet Child & Adolescent Health
- The Lancet Diabetes & Endocrinology
- The Lancet Digital Health
- The Lancet Gastroenterology & Hepatology
- The Lancet Global Health
- The Lancet Haematology
- The Lancet Healthy Longevity
- The Lancet HIV
- The Lancet Infectious Diseases
- The Lancet Microbe
- The Lancet Neurology
- The Lancet Oncology
- The Lancet Planetary Health
- The Lancet Psychiatry
- The Lancet Public Health
- The Lancet Regional Health – Americas
- The Lancet Regional Health – Europe
- The Lancet Regional Health – Southeast Asia
- The Lancet Regional Health – Western Pacific
- The Lancet Respiratory Medicine
- The Lancet Rheumatology
- eBioMedicine
- eClinicalMedicine
Highest standards for medical science
The Lancet sets extremely high standards. We select only the best research papers for their quality of work and the progression they bring.
Improving lives is the only end goal
Too much research is done for research sake. We believe that improving lives is the only end goal and that research is only relevant when it has an impact on human lives.
Increasing the social impact of science
We recognise that a great research paper is not enough and that it requires development, mobilisation, and exposure. So we promise to set agendas, create context, inform leaders, start debates, and advocate for the idea that research can and will make a difference.
Latest news and comment
Explore content in our collection to advance Equity, Diversity & Inclusion from accross The Lancet Group.
Antimicrobial resistance: an agenda for all
The Lancet Group's new guidance to authors on reporting race and ethnicity
Chew et al.
Artificial intelligence in medicine and the pursuit of environmentally responsible science
Gaetani et al.